154 related articles for article (PubMed ID: 36433814)
1. Circulating CD22+/CD19-/CD24- progenitors and CD22+/CD19+/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia.
Zhou T; Karrs J; Ho T; Doverte A; Kochenderfer JN; Shah NN; Yuan CM; Wang HW
Cytometry B Clin Cytom; 2023 Jul; 104(4):294-303. PubMed ID: 36433814
[TBL] [Abstract][Full Text] [Related]
2. 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
Chatterjee G; Dhende P; Raj S; Shetty V; Ghogale S; Deshpande N; Girase K; Patil J; Kalra A; Narula G; Dalvi K; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
Eur J Haematol; 2024 Jan; 112(1):122-136. PubMed ID: 37706583
[TBL] [Abstract][Full Text] [Related]
3. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
[TBL] [Abstract][Full Text] [Related]
4. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
Mikhailova E; Itov A; Zerkalenkova E; Roumiantseva J; Olshanskaya Y; Karachunskiy A; Novichkova G; Maschan M; Popov A
Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
7. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
8. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
[TBL] [Abstract][Full Text] [Related]
9. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
Cherian S; Miller V; McCullouch V; Dougherty K; Fromm JR; Wood BL
Cytometry B Clin Cytom; 2018 Jan; 94(1):112-120. PubMed ID: 27598971
[TBL] [Abstract][Full Text] [Related]
10. Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies.
Cherian S; Stetler-Stevenson M
Curr Protoc Cytom; 2018 Oct; 86(1):e44. PubMed ID: 30212602
[TBL] [Abstract][Full Text] [Related]
11. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E; Semchenkova A; Illarionova O; Kashpor S; Brilliantova V; Zakharova E; Zerkalenkova E; Zangrando A; Bocharova N; Shelikhova L; Diakonova Y; Zhogov V; Khismatullina R; Molostova O; Buldini B; Raykina E; Larin S; Olshanskaya Y; Miakova N; Novichkova G; Maschan M; Popov AM
Br J Haematol; 2021 May; 193(3):602-612. PubMed ID: 33715150
[TBL] [Abstract][Full Text] [Related]
12. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Liu S; Zhang X; Dai H; Cui W; Yin J; Li Z; Yang X; Yang C; Xue S; Qiu H; Miao M; Chen S; Jin Z; Fu C; Li C; Sun A; Han Y; Wang Y; Yu L; Wu D; Cui Q; Tang X
Blood Cancer J; 2023 Apr; 13(1):60. PubMed ID: 37095120
[TBL] [Abstract][Full Text] [Related]
13. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
15. Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
Gao Q; Liu Y; Aypar U; Baik J; Londono D; Sun X; Zhang J; Zhang Y; Roshal M
Cytometry B Clin Cytom; 2023 Jul; 104(4):279-293. PubMed ID: 36999235
[TBL] [Abstract][Full Text] [Related]
16. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
17. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
Verbeek MWC; van der Velden VHJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
[TBL] [Abstract][Full Text] [Related]
18. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
Baraka A; Sherief LM; Kamal NM; Shorbagy SE
Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
